Post-metabolic surgery pharmacological adjuvant
DOI:
https://doi.org/10.47196/diab.v56i3Sup.572Keywords:
obesity, diabetes mellitusAbstract
Treating type 2 diabetes mellitus (T2DM) in patients with obesity remains a challenge for physicians, endocrinologists and surgeons, a fact supported by uncontroverted evidence from studies looking at mortality and associated morbidity. Metabolic surgery remains the most effective treatment for obesity and T2DM. Two important limitations must be recognized and addressed. With regards to long-term remission of T2DM, the metabolic benefits of bariatric surgery appear to fatigue with time and a proportion of patients will not maintain normoglycaemia without pharmacotherapy. Second, there has been noteworthy progress in the development of several classes of medications for the treatment of T2DM. The recognition of the possibility of using pharmacotherapy to improve or maintain CM outcomes presents a new concept in the management of T2DM.
The proportion of patients who experience relapse of T2DM does not indicate a failure of CM; rather, it reflects the evolving nature of T2DM. The metabolic benefits of CM may attenuate over time, requiring other interventions such as pharmacotherapy to keep DM2 under control.
References
I. Aminian A, Vidal J, Salminen P, Still CD, Nor Hanipah Z, Sharma G, Tu C, et al. Late relapse of diabetes after bariatric surgery: not rare, but not a failure. Diabetes Care 2020 Mar;43(3):534-540.
II. Sudlow A, le Roux CW, Pournaras DJ. Review of multimodal treatment for type 2 diabetes: combining metabolic surgery and pharmacotherapy. Ther Adv Endocrinol Metab 2019;Vol 10:1-13.
III. Wharton S, Kamran E, Muqeem M, Khan A, Christensen RAG. The effectiveness and safety of pharmaceuticals to manage excess weight post-bariatric surgery: a systematic literature review. J Drug Assess 2019 Oct 17;8(1):184-191.
IV. Sudlow A, W le Roux C, J Pournaras D. Review of advances in anti-obesity pharmacotherapy: implications for a multimodal treatment approach with metabolic surgery. Obes Surg 2019 Dec;29(12):4095-4104.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 on behalf of the authors. Reproduction rights: Argentine Diabetes Society
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
